Regulatory requirements for vaccines intended to provide protection against variant strain(s) of SARS-CoV-2

The European CHMP has adopted a reflection paper which details the laboratory, clinical, quality and manufacturing data needed to support the approval of ‘variant’ vaccines, with the assumption they would largely rely on the same technology and platform as the ‘parent’ vaccine.

Source:

European Medicines Agency